Background:
- Malignant mesothelioma is a malignancy arising from the mesothelial cells of the
pleura, peritoneum, pericardium, or tunica vaginalis.
- Mesothelioma accounts for 0.10% of deaths annually in the United States. Malignant
pleural mesothelioma is the most common of these, comprising of 80% of the cases
with an annual incidence of about 2,500 in the United States.
- The median survival from diagnosis of pleural mesothelioma is approximately 12
months. The majority of patients present with stage III or IV disease with 85-90% of
patients considered unresectable at diagnosis.
- Peritoneal mesothelioma has a better prognosis than pleural mesothelioma;
nevertheless, patients undergoing therapy for peritoneal mesothelioma have few
well-studied treatment options due in large part to the rarity of the disease.
Objectives:
-To allow sample acquisition for use in the study of mesothelioma.
Eligibility:
- All patients age greater than or equal to 2 years with malignant mesothelioma
- Must be able and willing to provide informed consent if 18 or over; parent or
guardian must be able and willing to provide consent for patients under the age of
18
Design:
- Up to 1000 subjects will be enrolled.
- Patients will be followed to determine the course of disease and to record any
treatment received for mesothelioma.
- Patients will undergo sampling of blood, urine, tumor and abnormal body fluids for
tissue banking.
- Studies which may be performed on banked material include genetic and genomic
studies, establishment of cell cultures and immunologic studies.
Additional locations may be listed on ClinicalTrials.gov for NCT01950572.
Locations matching your search criteria
United States
Maryland
Bethesda
National Institutes of Health Clinical CenterStatus: Active
Contact: National Cancer Institute Referral Office
Phone: 888-624-1937
Background:
- Malignant mesothelioma is a malignancy arising from the mesothelial cells of the
pleura, peritoneum, pericardium, or tunica vaginalis.
- Mesothelioma accounts for 0.10% of deaths annually in the United States. Malignant
pleural mesothelioma is the most common of these, comprising of 80% of the cases
with an annual incidence of about 2,500 in the United States.
- The median survival from diagnosis of pleural mesothelioma is approximately 12
months. The majority of patients present with stage III or IV disease with 85-90% of
patients considered unresectable at diagnosis.
- Peritoneal mesothelioma has a better prognosis than pleural mesothelioma;
nevertheless, patients undergoing therapy for peritoneal mesothelioma have few
well-studied treatment options due in large part to the rarity of the disease.
- In addition to mesothelioma, mesothelin is highly expressed in several cancers,
including pancreatic, biliary adenocarcinomas, gastric and ovarian cancers;
mesothelin is also expressed in a significantly larger proportion of thymic
carcinoma than thymoma.
- Mesothelin expression level has been correlated with improved overall survival in
thymic cancer and with reduced overall survival in patients with lung cancer.
Objective:
-To allow sample acquisition for use in the study of mesothelioma and other mesothelin
expressing cancers.
Eligibility:
- All participants age greater than or equal to 2 years with malignant mesothelioma
- All participants age greater than or equal to 18 years with thymic carcinoma,
pancreatic or biliary adenocarcinoma or lung, gastric or ovarian cancers
- Must be able and willing to provide informed consent if 18 or over; parent or
guardian must be able and willing to provide consent for participants under the age
of 18
Design:
- Up to 1000 participants will be enrolled.
- Participants will be followed to determine the course of disease and to record any
treatment received for the eligible mesothelin expressing cancer.
- Participants will undergo sampling of blood, urine, tumor and abnormal body fluids
for tissue banking.
- Studies which may be performed on banked material include genetic and genomic
studies, establishment of cell cultures and immunologic studies.
Trial PhaseNo phase specified
Trial TypeNot provided by clinicaltrials.gov
Lead OrganizationNational Cancer Institute
Principal InvestigatorRaffit Hassan
